News Related to MSN

Related coverage linked through entity extraction aliases.

MSN Laboratories Gains CDSCO Approval for Generic Semaglutide in India

Mar 23, 2026

MSN Laboratories has received CDSCO approval for generic semaglutide, targeting a commercial launch by March 2026. The GLP-1 receptor agonist is used for type-2 diabetes management and will expand access to advanced metabolic therapies in India. The approval comes amid regulatory momentum and patent expirations driving generic entry into the market.

Natco Pharma Receives Approval for Generic Semaglutide in India, Launch Planned for March

Feb 13, 2026

Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.